VEGFA停药变异恶化心肌梗死的心脏重构。

IF 6 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS
Zhongxiang Chen, Diqi Zhu, Kaa Seng Lai, Yiwei Chen, Yuqing Hu, Yabo Fang, Zihang Yan, Beibei Hu, Zhen Zhang, Min Zhang, Fen Li
{"title":"VEGFA停药变异恶化心肌梗死的心脏重构。","authors":"Zhongxiang Chen, Diqi Zhu, Kaa Seng Lai, Yiwei Chen, Yuqing Hu, Yabo Fang, Zihang Yan, Beibei Hu, Zhen Zhang, Min Zhang, Fen Li","doi":"10.1161/CIRCGEN.124.004879","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>A sustained dosage of VEGFA (vascular endothelial growth factor A) is crucial for angiogenesis in both homeostasis and cardiovascular diseases. CUG-initiated alternative translation is a conserved mechanism for producing mature VEGFA. Genetic surveys have identified stop-gained variants predicted to prematurely terminate CUG-initiated translation without affecting ATG-initiated translation. However, the impacts of these variants on the vasculature in steady-state and disease conditions remain unknown.</p><p><strong>Methods: </strong>Using CRISPR/Cas9 genome editing, we established the <i>Vegfa</i><sup><i>Q150X/Q150</i></sup> allele (Q150X), a mouse genetic model that mimics the human VEGFA stop-gained variant. The effects of this variant were tested in both adult homeostatic conditions and the acute myocardial infarction (MI) model. We analyzed and quantified cardiac vasculature structure using immunofluorescence and light-sheet imaging. Furthermore, we characterized cellular heterogeneity, cell-cell interactions, and gene regulation using single-nucleus RNA sequencing, as well as cell type-specific transcriptomics and epigenomics.</p><p><strong>Results: </strong>Homozygous mice carrying the stop-gained variant were viable. VEGFA dosage was reduced to 70% in the Q150X homeostatic heart, with no significant alteration in cardiac function or vasculature. In the MI model, VEGFA dosage in Q150X was reduced to about 40% within the first week post-infarction, leading to functional deterioration in the post-MI hearts. Significant changes in cellular composition were observed 3 days post-MI. In particular, endothelial cells in Q150X diverged into a state that showed a higher level of hypoxia stress, an elevated inflammatory response, and increased extracellular matrix secretion. In addition, we observed an increase in Nppb<sup>+</sup> stressed cardiomyocytes in both 3 days post-MI and homeostasis. Finally, proinflammatory macrophages, neutrophils, and Cd8<sup>+</sup>T cells were enriched in the ischemic zone of Q150X hearts.</p><p><strong>Conclusions: </strong>CUG-initiated translation contributes significantly to the production of mature VEGFA in ischemic hearts. VEGFA dosage is critical in determining the cellular microenvironment during ischemic injury.</p>","PeriodicalId":10326,"journal":{"name":"Circulation: Genomic and Precision Medicine","volume":" ","pages":"e004879"},"PeriodicalIF":6.0000,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"VEGFA Stop-Gained Variant Deteriorates Cardiac Remodeling in Myocardial Infarction.\",\"authors\":\"Zhongxiang Chen, Diqi Zhu, Kaa Seng Lai, Yiwei Chen, Yuqing Hu, Yabo Fang, Zihang Yan, Beibei Hu, Zhen Zhang, Min Zhang, Fen Li\",\"doi\":\"10.1161/CIRCGEN.124.004879\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>A sustained dosage of VEGFA (vascular endothelial growth factor A) is crucial for angiogenesis in both homeostasis and cardiovascular diseases. CUG-initiated alternative translation is a conserved mechanism for producing mature VEGFA. Genetic surveys have identified stop-gained variants predicted to prematurely terminate CUG-initiated translation without affecting ATG-initiated translation. However, the impacts of these variants on the vasculature in steady-state and disease conditions remain unknown.</p><p><strong>Methods: </strong>Using CRISPR/Cas9 genome editing, we established the <i>Vegfa</i><sup><i>Q150X/Q150</i></sup> allele (Q150X), a mouse genetic model that mimics the human VEGFA stop-gained variant. The effects of this variant were tested in both adult homeostatic conditions and the acute myocardial infarction (MI) model. We analyzed and quantified cardiac vasculature structure using immunofluorescence and light-sheet imaging. Furthermore, we characterized cellular heterogeneity, cell-cell interactions, and gene regulation using single-nucleus RNA sequencing, as well as cell type-specific transcriptomics and epigenomics.</p><p><strong>Results: </strong>Homozygous mice carrying the stop-gained variant were viable. VEGFA dosage was reduced to 70% in the Q150X homeostatic heart, with no significant alteration in cardiac function or vasculature. In the MI model, VEGFA dosage in Q150X was reduced to about 40% within the first week post-infarction, leading to functional deterioration in the post-MI hearts. Significant changes in cellular composition were observed 3 days post-MI. In particular, endothelial cells in Q150X diverged into a state that showed a higher level of hypoxia stress, an elevated inflammatory response, and increased extracellular matrix secretion. In addition, we observed an increase in Nppb<sup>+</sup> stressed cardiomyocytes in both 3 days post-MI and homeostasis. Finally, proinflammatory macrophages, neutrophils, and Cd8<sup>+</sup>T cells were enriched in the ischemic zone of Q150X hearts.</p><p><strong>Conclusions: </strong>CUG-initiated translation contributes significantly to the production of mature VEGFA in ischemic hearts. VEGFA dosage is critical in determining the cellular microenvironment during ischemic injury.</p>\",\"PeriodicalId\":10326,\"journal\":{\"name\":\"Circulation: Genomic and Precision Medicine\",\"volume\":\" \",\"pages\":\"e004879\"},\"PeriodicalIF\":6.0000,\"publicationDate\":\"2025-07-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Circulation: Genomic and Precision Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1161/CIRCGEN.124.004879\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Circulation: Genomic and Precision Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1161/CIRCGEN.124.004879","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

背景:持续剂量的VEGFA(血管内皮生长因子A)对于体内平衡和心血管疾病的血管生成都是至关重要的。cug启动的替代翻译是产生成熟VEGFA的保守机制。遗传调查已经确定了停止获得的变异,预测过早终止cug启动的翻译,而不影响atg启动的翻译。然而,在稳态和疾病条件下,这些变异对脉管系统的影响尚不清楚。方法:利用CRISPR/Cas9基因组编辑技术,建立模拟人类VEGFA停获变异体的小鼠遗传模型VegfaQ150X/Q150等位基因(Q150X)。在成人体内平衡条件和急性心肌梗死(MI)模型中测试了这种变异的影响。我们使用免疫荧光和光片成像分析和定量心脏血管结构。此外,我们利用单核RNA测序以及细胞类型特异性转录组学和表观基因组学表征了细胞异质性、细胞间相互作用和基因调控。结果:携带停止获得变异的纯合子小鼠存活。在Q150X稳态心脏中,VEGFA剂量减少到70%,心功能或脉管系统没有明显改变。在心肌梗死模型中,Q150X的VEGFA剂量在梗死后第一周内减少到40%左右,导致心肌梗死后心脏功能恶化。心肌梗死3天后,细胞成分发生显著变化。特别是,Q150X的内皮细胞分化为缺氧应激水平升高、炎症反应升高、细胞外基质分泌增加的状态。此外,我们观察到心肌梗死后3天内Nppb+应激心肌细胞的增加和内稳态。最后,促炎巨噬细胞、中性粒细胞和Cd8+T细胞在Q150X心脏缺血区富集。结论:cug启动的翻译对缺血心脏成熟VEGFA的产生有重要作用。VEGFA的剂量是决定缺血损伤期间细胞微环境的关键。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
VEGFA Stop-Gained Variant Deteriorates Cardiac Remodeling in Myocardial Infarction.

Background: A sustained dosage of VEGFA (vascular endothelial growth factor A) is crucial for angiogenesis in both homeostasis and cardiovascular diseases. CUG-initiated alternative translation is a conserved mechanism for producing mature VEGFA. Genetic surveys have identified stop-gained variants predicted to prematurely terminate CUG-initiated translation without affecting ATG-initiated translation. However, the impacts of these variants on the vasculature in steady-state and disease conditions remain unknown.

Methods: Using CRISPR/Cas9 genome editing, we established the VegfaQ150X/Q150 allele (Q150X), a mouse genetic model that mimics the human VEGFA stop-gained variant. The effects of this variant were tested in both adult homeostatic conditions and the acute myocardial infarction (MI) model. We analyzed and quantified cardiac vasculature structure using immunofluorescence and light-sheet imaging. Furthermore, we characterized cellular heterogeneity, cell-cell interactions, and gene regulation using single-nucleus RNA sequencing, as well as cell type-specific transcriptomics and epigenomics.

Results: Homozygous mice carrying the stop-gained variant were viable. VEGFA dosage was reduced to 70% in the Q150X homeostatic heart, with no significant alteration in cardiac function or vasculature. In the MI model, VEGFA dosage in Q150X was reduced to about 40% within the first week post-infarction, leading to functional deterioration in the post-MI hearts. Significant changes in cellular composition were observed 3 days post-MI. In particular, endothelial cells in Q150X diverged into a state that showed a higher level of hypoxia stress, an elevated inflammatory response, and increased extracellular matrix secretion. In addition, we observed an increase in Nppb+ stressed cardiomyocytes in both 3 days post-MI and homeostasis. Finally, proinflammatory macrophages, neutrophils, and Cd8+T cells were enriched in the ischemic zone of Q150X hearts.

Conclusions: CUG-initiated translation contributes significantly to the production of mature VEGFA in ischemic hearts. VEGFA dosage is critical in determining the cellular microenvironment during ischemic injury.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Circulation: Genomic and Precision Medicine
Circulation: Genomic and Precision Medicine Biochemistry, Genetics and Molecular Biology-Genetics
CiteScore
9.20
自引率
5.40%
发文量
144
期刊介绍: Circulation: Genomic and Precision Medicine is a distinguished journal dedicated to advancing the frontiers of cardiovascular genomics and precision medicine. It publishes a diverse array of original research articles that delve into the genetic and molecular underpinnings of cardiovascular diseases. The journal's scope is broad, encompassing studies from human subjects to laboratory models, and from in vitro experiments to computational simulations. Circulation: Genomic and Precision Medicine is committed to publishing studies that have direct relevance to human cardiovascular biology and disease, with the ultimate goal of improving patient care and outcomes. The journal serves as a platform for researchers to share their groundbreaking work, fostering collaboration and innovation in the field of cardiovascular genomics and precision medicine.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信